Share This Page
Drugs in ATC Class A09AB
✉ Email this page to a colleague
Drugs in ATC Class: A09AB - Acid preparations
| Tradename | Generic Name |
|---|---|
| RENACIDIN | citric acid; gluconolactone; magnesium carbonate |
| PHEXX | citric acid; lactic acid; potassium bitartrate |
| IRRIGATING SOLUTION G IN PLASTIC CONTAINER | citric acid; magnesium oxide; sodium carbonate |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class A09AB (acid preparations): exclusivity timelines, Orange Book coverage, and generic entry risk
ATC A09AB (“acid preparations”) is a niche segment where patent protection is fragmented by product and indication. The key commercial risk for sponsors is early erosion from generic acid salts and branded reformulations, while patent leverage is more likely to come from combination products, specific dosing regimens, and manufacture-specific polymorph or stability claims than from broad platform coverage across the whole class.
What does ATC A09AB “acid preparations” include and which products drive revenue?
Quick answer: A09AB is a class label for acid-based digestive/upper-GI supportive therapies (typically oral acid formulations used to support digestion, supplement gastric acidity, or support GI conditions). Revenue within the class concentrates in a small number of legacy branded products plus generics of acid salts and buffered/controlled-release variants sold under multiple label indications.
Typical A09AB subtypes by product design (what to screen in patent estates)
Patent and regulatory artifacts in this space tend to cluster around four technical motifs:
- Acid salts or acid mixtures (e.g., hydrochloric-acid supplying or acid/base buffering systems)
- Buffered formulations that modulate release and gastric pH microenvironment
- Enteric or controlled-release designs that reduce premature degradation in the upper GI tract
- Combination products pairing acid with digestive enzymes or co-factors to support a defined therapeutic outcome
How market dynamics shape patent value
- Low manufacturing complexity for simple acid salts increases generic substitution.
- Formulation sensitivity (stability, palatability, shelf-life, dissolution behavior) increases the patent surface for later-life reformulations.
- Label-driven exclusivity matters more than broad claims: method-of-use and regimen claims tied to specific indication language can constrain generic labeling even when active ingredient patents are weak.
Which patents protect acid preparations (A09AB) in the US and how many are typically actionable?
Quick answer: In A09AB, the actionable patent estate is usually concentrated in formulation patents (composition, solid-state, stability), method-of-use patents tied to a label indication, and limited device/manufacturing patents. Active-ingredient process patents are less commonly a durable barrier because generic acid salts can be produced via multiple routes.
Patent categories that repeatedly show up in A09AB-like estates
- Composition of matter: specific acid salt combinations, buffering ratios, excipient systems
- Polymorph/crystal form: less common but decisive when claimed for stability and release
- Manufacturing process: coating, granulation, mixing sequence claims used to differentiate dosage forms
- Stability and shelf-life claims: storage stability, moisture control, degradation profiles
- Method-of-use: treating defined GI conditions by administering an acid preparation in a defined dose schedule
- Label-specific dosing: “administer X with meals,” “before meals,” or regimen windows used to block design-around labeling
What to expect in Orange Book coverage for A09AB-style products
- Branded product listings often show one to a handful of patents per NDA/NADA active label.
- Generics often launch once the listed formulation patents expire, unless a later-life reformulation patent is Orange-Book listed for the same product strength/dosage form.
When does exclusivity end for acid preparations (A09AB): patent expiration vs FDA exclusivity
Quick answer: For acid preparations, practical generic entry timing usually follows patent expiration for listed formulation and method-of-use patents, not FDA exclusivity extensions, because many products rely on older composition know-how rather than new clinical exclusivity.
Two parallel clocks that control entry
-
Patent clock
- Composition and formulation patents: typically 17 to 20 years from priority, with later filings extending the edge.
- Method-of-use patents: can extend barriers even after active ingredient commoditization.
-
Regulatory exclusivity clock
- Data exclusivity (5-year New Chemical Entity or 7-year for some conditions) is less likely for older acid salts, but reformulations or new combination products can reset barriers.
“Loss of exclusivity” in A09AB
- If a branded acid product has multiple strengths, patents may expire unevenly by strength/dosage form.
- Generics can enter at a subset of strengths first, then expand after additional patent expiries.
What generic entry risks exist for A09AB: Paragraph IV, ANDA triggers, and design-around strategies?
Quick answer: Paragraph IV risk in A09AB is concentrated in products with Orange-Book-listed formulation and dosing/regimen patents. Where the active ingredient is a commodity acid salt, generic challenges target the last-mile barriers: buffering system claims, stability claims, and specific administration regimens.
How ANDA sponsors typically design around in this class
- Formulation substitution: alternate buffering agents/excipients to avoid “essentially the same” claim language.
- Release profile changes: different excipient matrix, granulation, or coating approach to avoid dissolution-related claim elements.
- Label strategy: narrow or avoid claimed dosing schedules to reduce risk of method-of-use infringement, though this can trigger carve-outs and settlement restrictions.
Typical litigation triggers
- Orange-Book patent listings with claims covering:
- specific excipient ratios
- stability thresholds (e.g., degradation under defined conditions)
- a dosing algorithm tied to an indication
What is the Orange Book status of key acid preparations and what patents are listed?
Quick answer: A09AB assets are not a single monolith; Orange Book status is product-specific. The main operational work is mapping each branded acid product’s Orange Book patent list into a strength-by-strength expiration matrix and pairing that with ANDA filings and litigation.
How to build an Orange Book-to-risk matrix (format that drives decisions)
For each branded product:
- NDA/label identifier
- Patent number
- Patent type (composition, formulation, method-of-use, manufacturing)
- Expiration date
- Listed strength/dosage form
- Any regulatory exclusivity end date
- Current ANDA activity (if known from FDA/press/lit sources)
This produces a “generic launch horizon” that commercial teams can directly use for forecasting and licensing strategy.
How strong is the patent estate for acid preparations: claim scope, enforceability, and typical vulnerabilities
Quick answer: Strength is often medium-to-low for baseline compositions and higher for tightly drafted formulation features. Common vulnerabilities include obviousness of buffering/excipient combinations and weak inventive concept where prior art covers similar acid salts and standard pharmaceutical excipients.
Enforceability pressure points in acid-preparation patents
- Obviousness over prior art: buffering and excipient selection can be viewed as routine optimization.
- Indefiniteness risk: stability claims using broad functional language can be challenged if the specification does not provide a clear test boundary.
- Design-around feasibility: generic reformulation can avoid claim elements while staying within therapeutic equivalence.
- Method-of-use labeling carve-outs: settlements often resolve by negotiated label changes rather than invalidating core patents.
What patent litigation affects A09AB acid preparations and what settlement patterns occur?
Quick answer: Litigation patterns in this segment usually resolve via settlement agreements that:
- permit generic launch on a timeline
- impose label restrictions (dosing instructions or indication narrowing)
- allocate carve-outs by strength/dosage form
Common settlement terms that matter commercially
- Launch date tied to the expiration of specific listed patents
- Narrowed label language to avoid method-of-use infringement theories
- Royalty or pay-to-delay style terms (jurisdiction-dependent), often confidential but sometimes partially disclosed via filings or press
- Obligation to cease certain promotional claims tied to the patent theory
How do biosimilar risks apply to A09AB acid preparations?
Quick answer: Biosimilars are not relevant to ATC A09AB in the normal case because this class is not biologic-based. The competitive risk is generic small molecules and reformulation entrants, not biosimilar biologics.
How do combination acid preparations compare with single-acid products in patent coverage?
Quick answer: Combination products tend to carry a larger and more durable patent estate because the sponsor can claim:
- specific pairing ratios
- synergistic use (dose scheduling)
- stability advantages for the combination
- method-of-use tied to combination therapy outcomes
Typical comparison logic
- Single-acid products: fewer patents, faster erosion.
- Combination acid + enzymes or co-factors: more patents across composition and dosing, higher likelihood of Orange-Book listings that block generic substitution.
What formulation patents are protected for acid preparations (A09AB): solid state, stability, and controlled release
Quick answer: The most defensible patents in A09AB usually protect the dosage form physics: buffering system behavior, stability under defined conditions, and controlled release.
Formulation claim hooks to screen for in patent text
- Specific buffering ratios
- Chosen excipient families that govern release or moisture sensitivity
- Particle size distributions or granulation method constraints
- Coating specifications for enteric or delayed release
- Stability test thresholds with quantified degradation endpoints
Which companies are challenging or defending acid preparation patents?
Quick answer: The defense side is typically branded product holders and their branded owners, while challenge activity is usually concentrated in established ANDA filers that target formulation patents where the active ingredient is commodity.
How to map challenger behavior (actionable framework)
- Identify ANDA filers per branded product strength
- Correlate with which patent numbers they target in Paragraph IV notices
- Track whether litigation leads to:
- a design-around approval
- label carve-outs
- delayed entry due to settlement
What is the commercial impact of the patent timeline for A09AB acid preparations?
Quick answer: In A09AB, revenue exposure concentrates in the period after formulation and method-of-use patents expire. Generic entry can occur quickly once the last Orange-Book listed barriers clear, because the active ingredients are typically not protected broadly.
Commercial planning approach
- Build strength-specific launch calendars
- Treat reformulation patents as “second wave blockers”
- Model price compression post-launch and account for label carve-outs that may preserve some branded differentiation
Key Takeaways
- Patent protection in A09AB is product-specific and usually hinges on formulation and method-of-use patents rather than broad active-ingredient coverage.
- Generic entry timing follows Orange-Book listed patents and any method-of-use labeling theories, with practical erosion often occurring shortly after the last listed formulation barrier expires.
- Litigation and settlements in this niche typically lead to scheduled launches and label carve-outs rather than full invalidation of patent estates.
- Combination acid preparations generally carry stronger, broader patent coverage than single-acid products, raising the odds of longer exclusivity for those products.
FAQs
1) How do formulation patents for acid preparations block ANDA approval even when the API is generic?
They protect excipient systems, buffering ratios, release profiles, and stability thresholds that ANDAs must replicate to be considered equivalent.
2) What patent claim types are most frequently targeted in Paragraph IV challenges for acid preparations?
Composition/formulation and method-of-use patents tied to dosing regimens and label language are typical targets.
3) Can generics launch at some strengths of an A09AB product before others?
Yes, if patent expiry differs by listed strength/dosage form, enabling partial product-line entry.
4) Do stability-based patents create enforceable barriers for generic manufacturers in A09AB?
They can, but enforceability depends on claim clarity and whether test conditions and endpoints map to the generic’s demonstrated stability.
5) Are there manufacturing/IP hurdles beyond formulation claims for acid preparations?
Yes, process-related claims can matter when they are tightly tied to the claimed product characteristics, especially for coated or controlled-release forms.
References
No sources were cited because product-level Orange Book, patent, ANDA, and litigation data specific to ATC A09AB assets were not provided in the prompt.
More… ↓
